NetworkNewsWire Editorial Coverage: With sales of carbonated drinks steadily declining for more than a decade, major players in the space are eager to find ways to expand their portfolios into the booming craft beverages and bottled water sectors. One way to accomplish that may be the M&A route, with companies such as The Alkaline Water Company (NASDAQ: WTER)(CSE: WTER) (WTER Profile), one of the fastest-growing enhanced water companies in the industry, looking like an attractive option. In the meantime, Coca-Cola Company (NYSE: KO) is making strides on its previously announced Beverages for Life strategic transformation. New Age Beverages Corporation (NASDAQ: NBEV) has entered into a definitive agreement to acquire ARIIX, together with four additional companies in the e-commerce and direct-selling channels. Nestle (OTC: NSRGY) is sharpening its water focus on international, premium mineral and functional brands while exploring strategic options for parts of its North American business. And Monster Beverage Corporation (NASDAQ: MNST) is reporting sequential improvement in sales during the latter-half of the quarter after seeing a dip in sales earlier in the quarter.

• Sales in the carbonated soft drink category have been sliding for 15 years.
• New market share may be available through specialty and niche market beverage makers.
• Major players may see The Alkaline Water Company as an attractive M&A candidate.
• Reporting record growth over the past quarter, WTER is eyeing continued success moving forward.

Trends Impacting Soft Drink Sales

Recently, a “Beverage Industry” article reported that volume sales in the carbonated soft drink category have declined for 15 consecutive years. “Today’s consumers want both variety and healthier refreshment, trends which have negatively impacted carbonated soft drinks,” said Gary Hemphill, managing director of research for New York-based Beverage Marketing Corporation.

In the same article, Jacqueline Hiner, industry analyst for Los Angeles-based IBISWorld, noted that “the most prominent driver of this trend is the higher number of health-conscious individuals in conjunction with rising per capita disposable income. Rising disposable income levels enable consumers who enjoy the taste of carbonated beverages to splurge on craft beverages that are made with natural ingredients. However, growth in this market is expected to be tempered by the continued increase in health consciousness driving consumers to drink water.”

As Hiner noted, while soda sales are down, sales of bottled water worldwide are rising. Pre-pandemic, Americans spent $18.5 billion on bottled water annually; that number was projected to rise to $22 billion by the end of 2024. According to Grand View Research, the global bottled water market is expected to reach $215.12 billion by 2025 — posting a compound annual growth rate of 7.4% over the next six years. These numbers could end up even higher as health-conscious consumers opt for water over soda.

An Enhanced Appeal

Major beverage makers can’t ignore what looks like the future of beverages. As these large companies evaluate the forecast numbers, savvy soda companies are looking for strategic ways to get in on the action. One path that many of the larger companies are pursuing is mergers and acquisitions. Examples include Coca-Cola’s acquisition of Vitamin Water for $4.2 billion and Reignwood’s $105-million acquisition of Voss. Dr. Pepper has taken the M&A route too, acquiring Core for $525 million and Bai for $1.2 billion.

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) could be a prime target for any company considering this type of strategic consolidation. One of the fastest-growing enhanced water companies in the country, WTER has reported an astonishing 62% compound annual sales growth rate over the last five years. The company posted record annual revenue of $41.1 million as health-conscious consumers have turned away from sugary soft drinks to bottled water, particularly water that’s been enhanced.

The pandemic has only boosted the company’s appeal. While other beverage companies struggled to put their drinks on the shelf, The Alkaline Water Company delivered record growth over the past quarter. The company reported record sales in March ($6.2 million) and April ($7.1 million), representing year over year growth of 114% and 171% respectively.

WTER was one of the few water brands able to deliver during the peak “pantry-stuffing” period, resulting in an estimated 30–40% of new households quenching their thirst with Alkaline88 for the first time — the largest sampling program in the company’s history. In fact, a recent Nielsen report ranked Alkaline88(R) as the 10th best-selling value-added water and the third fastest-growing, top-ten, value-added water in the country during the 13 weeks ending May 16, 2020.

A Strong Track Record

The Alkaline Water Company’s upward trajectory appears likely to continue.

Alkaline88 remains one of the top-selling brands in the value-added water category. According to recent trade data, Alkaline88 reported double-digit growth despite the value-added water category contracting 8.2% for the four-week period ending April 18, 2020.

In addition, the company’s track record of identifying and meeting consumers’ needs is well documented. Last year, the company launched A88 Infused(TM) to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven all-natural flavors, with new flavors on their way.

Another consideration is WTER’s strong commitment to the environment. The company began 2020 by unveiling its flagship brand, Alkaline88, available in 500ml, single-serving aluminum bottles. “Consumers are demanding more eco-friendly choices, and we are excited to now offer a refillable, resealable, and 100% recyclable option,” said company president and CEO Richard A, Wright. “This is yet another step that the company is taking toward a more renewable future, and we remain committed to providing smarter and innovative packaging solutions for the environmentally conscious consumer.” The company has proven incredibly adept at identifying and delivering on consumer demands.

Strong Indicators for Continued Growth

The Alkaline Water Company has other strong indicators for its continued growth moving forward, including its entrance into the hospitality space and expansion of its e-commerce presence to meet new consumer buying habits.

The company recently reported that its products will be available in more than 15,000 new retail locations; with those new numbers, WTER products can now be found in an estimated 70,000 retail stores in all 50 states across the country. In addition, the company has identified an additional 40,000 retail locations it is eyeing for further expansion in fiscal 2021.

With a solid sales pipeline in new and existing markets, Alkaline’s robust lineup of innovative products, and growing momentum in its lifestyle brands, The Alkaline Water Company may be a tremendous opportunity for investors interested in a high-growth company that has a strong track record of delivering on its promises. Of course, becoming a target for the majors would be an added bonus.

Opportunities for Growth, Success

Health and wellness trends have certainly made a dent in the beverage industry. The downward trend appears to be further fueled by the global pandemic. Large companies in the space are looking for ways to maintain and even expand market share.

Coca-Cola Company (NYSE: KO) recently announced that plans to streamline its beverage lineup and modernize its marketing have been escalated by the COVID-19 pandemic. The company’s Beverages for Life strategic transformation was well underway before the pandemic, but the global crisis is speeding the changes. The company outlined plans to drive this strategy through a more networked global organization led by nine operating units, five marketing category leadership teams and a new Platform Services organization.

Health and wellness is the focus of the new global firm created by NewAge Inc (NASDAQ: NBEV). The omni-channel Colorado-based healthy and organic products company and ARIIX have agreed to create a leading health and wellness firm with a unique route to market, depth in the e-commerce and direct-selling channels, a team of more than 400,000 independent representatives, and a portfolio of healthy products unrivaled in the industry. Other companies involved in the endeavor include Zennoa, LIMU, MaVie and Shannen; the combined companies are creating a global firm with estimated pro forma revenues in excess of $500 million across more than 75 countries worldwide.

Nestle SA’s (OTC: NSRGY) Board of Directors approved a new strategic direction for its waters business. The company will sharpen its focus on its iconic international brands, its leading premium mineral water brands, and invest in differentiated healthy hydration, such as functional water products. The board also confirmed its intent to explore strategic acquisitions to grow in this category, while pledging to make its entire global water portfolio carbon neutral and replenish associated watersheds by 2025.

Despite COVID-19, Monster Beverage Corporation (NASDAQ: MNST) has announced that all of the company’s flavor manufacturing facilities, co-packers, warehouses and shipment facilities are operating. Safety precautions have been instituted, which were developed and adopted in line with guidance from public health authorities and professional consultants. While Monster’s second-quarter net and gross sales were adversely impacted by pandemic, the company is seeing an improvement in sales as certain countries and states begin to gradually re-open.

The news isn’t all bad for those involved in the beverage world. Smart companies are making strategic decisions to move in directions that make the most of opportunities for growth and success.

For more information about The Alkaline Water Company, please visit The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER).

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

For the past few years, China has had the largest electric vehicle (“EV”) market on the globe. Although the electric vehicle market is still growing, China has consistently managed to bag a large percentage of it, at least until recently. According to a new report from Bloomberg, the European electric vehicle sales have finally surpassed the Chinese market for the first time since 2015. The European EV market kept growing due to Europe’s automotive CO2 regulations as well as new model launches from automakers, despite the coronavirus pandemic.

Bloomberg reports that around 380,000 electric vehicles were sold in the first six months over the 16 main European markets. Over the first eight months of 2020, people across Western Europe bought over half a million electric cars, according to the European Electric Car Report industry publication. On the other hand, China, widely considered the world’s biggest market for EVs, saw a 44% drop in sales to around 330,000 electric cars.

The increase in sales can be attributed to a combination of new subsidy schemes to make electric vehicles more affordable. These include government, fiscal, and original equipment manufacturer (“OEM”) subsidies. It can also be attributed to the CO2 emissions standards created by the European Union (“EU”) as well as policies at state and municipal levels that have made it possible to invest in new charging infrastructure and electric cars. Germany and France, for instance, have made subsidies for electric vehicles an integral part of their coronavirus recovery packages.

On the other hand, China experienced a drop in sales in the middle of 2019 after it reduced its subsidy for programs for the new technology. The subsidies were later reinstated but according to the China Association of Automobile Manufacturers (“CAAM”), sales are likely to drop 10% this year compared to 2019.

Of the 597,000 electric vehicles sold in Western EU countries over the first eight months of 2020, 313,000 were battery electric vehicles (“BEVs”) and 279,000 were plug-in hybrid electric vehicles (“PHEVs”). CAAM reports that during the same period, China sold 332,000 personal BEVs, 105 personal PHEVs as well as 46,000 commercial BEVs and 3,000 commercial PHEVs for a total of 486,000 units.

Although the Chinese government has put forth subsidies to help the EV market, the sales numbers are expected to stay low, at least in the near future. As the coronavirus pandemic emerges again and again, customers will be forced to stay indoors and avoid large purchases until the virus is contained. If Europe manages to get the pandemic in control before China, it will be able to hold on to its position as the largest EV market in the world.

Analysts say companies like Net Element (NASDAQ: NETE) are glad to see the numbers of electric vehicles sold in Europe and elsewhere rising as this augers well for the fight against vehicular carbon emissions.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Researchers from the Georgia Institute of Technology and Ohio State University have discovered a way to send soft tiny robots into humans. This may open the door for ways to deliver treatments for various conditions ranging from aortic artery blockages to colon polyps as well as less invasive surgical procedures.

The comprehensive study, which uses origami, an ancient Japanese practice, was published in the Proceedings of the National Academy of Sciences on September 14.

Renee Zhao, an assistant professor of mechanical and aerospace engineering at Ohio State University and the co-author of the paper, stated that using this method, doctors utilize magnetic fields to help guide the soft robot as it ferries treatments or medications to the regions that need them in the body.

The robot is made of a soft composite which has magnetic particles embedded, which means it can be controlled remotely using magnetic fields. As compared to our current technologies, the robot is significantly less invasive. This is not to mean that this is the first time robots have been used to deliver medical treatments. However, this is the first design that uses a ‘soft’ component unlike the traditional robots that are made of hard, stiff materials.

Zhao adds that the “soft” part of the robot is vital as the material offers the advantage of not using tethers, controllers or motors, to facilitate its introduction into the body as well as its movement to its destination.

Based on the independently controlled folding and deployment of the origami unit, the soft origami robot may be used to deliver treatments selectively. The origami allows the material to release the treatment when it reaches its destination, spreading the treatment along with it and applying it to the organ or tissue that needs it.

While previous origami-style medication delivery systems are also not new, prior designs relied on bulky and cumbersome ways of activating the origami to deliver the treatments. Other systems did not allow for the treatments to be delivered to an exact location in the body.

With this robot, bulkiness is eliminated and as elaborated in the study, the researchers used magnetic fields in the lab to control the speed, intensity and direction of the material’s folding and its deployment.

However, the robot is yet to be used in the human body as the research was conducted in a lab. The researchers believe that the technology could enable doctors to control the robot remotely using magnetic fields alone.

Glaucio Paulino, the paper’s co-author, anticipates that the magnetic origami system will have many other applications in the future beyond their use in the medical field. It would be interesting to hear what DarioHealth Corp. (NASDAQ: DRIO) sees as the possible life-saving uses for this robot.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer.
• In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit.
• In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation.
• A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade.
• Industry reports estimate that the global brain tumor therapeutics market will reach $2.74 billion in 2023 and $3.4 billion by 2025, up from $2.25 billion in 2019.

CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (“API”) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://ibn.fm/BIvsS).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• SGTM secures Hurricane Laura recovery work contract for ArborPro of Mississippi Inc.
• Initial relief efforts will divert trees from landfills to temporary holding sites
• SGTM transforms natural storm waste into organic environmentally beneficial products

As “stewards of the environment”, Sustainable Green Team (OTC: SGTM) takes its role in environmental remediation seriously by providing beneficial solutions for tree and storm waste disposal. In the wake of Hurricane Laura, SGTM rose to the occasion by securing a contract for ArborPro of Mississippi Inc. (APM), one of its strategic partners. The recovery work planned will kickstart SGTM’s process, diverting many destroyed trees from landfills to the company’s processing facilities that will transform them into environmentally beneficial organic products.

Considered to be the strongest hurricane to hit Louisiana since 1856, Laura ravaged the state with winds clocking in at over 150 miles per hour as it destroyed vegetation and shredded homes while taking at least 17 lives in the process (http://nnw.fm/XHCjb). Hurricanes of this magnitude inflict massive damage on trees by breaking branches or uprooting them completely, creating a burden for municipalities that often dispose of them in landfills.

SGTM provides synergistic solutions that clear devastated areas of natural waste while creating products that benefit the environment. Through its subsidiary National Storm Recovery, the company collects the trees and transforms them into organic products such as garden mulch and organic playground surfacing material certified by IPEMA, The International Play Equipment Manufacturers Association.

“Our teams are committed to the cleanup process and helping the wonderful people of Louisiana get back on their feet again,” said SGTM CEO and Director Tony Raynor (http://nnw.fm/H2Fwm). “Our database of subcontractors is growing daily as the clean-up efforts begin.”

Teams from both SGTM and APM will initially collaborate with subcontractors to remove trees blocking key infrastructure points such as right-of-ways. As part of the initial remediation efforts, the trees will then be transported to temporary debris management sites for storage prior to reaching their final destination at SGTM’s processing facilities.

“I’m proud to be a part of this disaster recovery clean up and with our relationship with National Storm Recovery,” said APM CEO Aaron Miller. “Our combined resources and decades of experience will speed the recovery process.”

SGTM’s solutions are founded in sustainability, based on vertically integrated operations that transform what would be landfill waste into organic, attractive, next-generation playground surface material and mulch products that are packaged and sold to landscapers, installers and garden centers. Through a combination of organic growth, strategic acquisitions and service diversification, the company is positioned for rapid growth as nationwide demand for environmentally sustainable solutions for natural waste continues to increase.

To learn more about Sustainable Green Team Ltd., view the investor presentation at http://nnw.fm/UpXmd.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://nnw.fm/SGTM

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• Pressing need for efficient drug procurement, delivery as costs rise
• Trxade platform speeds up delivery, cuts costs
• Such efficiencies crucial to keeping America’s independent pharmacies alive
• Around half of 24,000 independent pharmacies have already signed on

These days, critics of the U.S. health-care system may be tempering their censure. After all, the sector has proved its worth in the battle against the coronavirus pandemic. Yet some of the fault-finding had merit. The system is bloated and plagued by inefficiencies. Even doctors agree, as a recent report in the “Journal of the American Medical Association” (“JAMA”) indicates (http://nnw.fm/hPid6). Digital technologies may help streamline processes and methodologies, making some areas, such as pharmaceutical distribution, more efficient and, importantly, more effective. With that in mind, the Trxade Group (NASDAQ: MEDS) has developed a pharmaceutical supply-chain trading platform that is already helping pharmacies cut costs and get faster delivery.

No other country spends more on health care than the United States. National expenditure in the sector accounts for around 18% of gross domestic product (“GDP”). Unfortunately, recent studies have shown a lot of that money just goes down the drain. That conclusion, published in JAMA, details that “approximately 30% of health care spending may be considered waste.”

A major portion of that — $230.7 billion to $240.5 billion — can be attributed to “pricing failure,” which includes “medication pricing, payer-based health services pricing, and laboratory-based and ambulatory pricing.” Of these, medication pricing is posing the biggest challenge, as new high-cost specialty drugs become more widely prescribed. But, say researchers, cost pressures in pharmaceuticals can be reduced by “increasing market competition… and reforming price transparency,” which is exactly what the Trxade pharmaceutical trading platform is designed to do (http://nnw.fm/Wy96V).

The web-based platform allows pharmacies to discover the best-available prices for prescription drugs, a feature that independent pharmacists find especially advantageous. It also helps pharmacies avoid negative reimbursement costs, which reduce already thin profit margins. The Trxade Group is hoping to show most, if not all, of the 24,000 independent pharmacies that its platform is a better deal than the conventional system, and the company appears well on the way to doing so. An estimated 11,400 pharmacies have already signed up.

These cost pressures are particularly trying for independent pharmacies that are competing with giant chains such as CVS, Walgreens, Rite Aid and Walmart. In the past, these smaller businesses have depended on pharmacy benefit managers (“PBMs”) to reduce the purchase costs of drugs. PBMs are third-party administrators of prescription drug programs that were supposed to contribute to lower prices by their consolidation of buying power.

However, it appears the cost savings procured have been mainly used by PBMs to build their own businesses. Some PBMs now have revenues that exceed those of the top pharmaceutical manufacturers. For example, Express Scripts reported revenue of $100 billion in 2017, about twice as much as Pfizer, which is the largest pharmaceutical company in the world. Incredible as it may seem, the distribution of pharmaceuticals is a much more lucrative business than the manufacture of pharmaceuticals. Indeed, distribution margins also exceed those earned by pharmacies at the retail level.

However, the online marketplace hosted by the Trxade Group offers pharmacies a real opportunity to reduce purchase costs. Called the Trxade Exchange, the platform gives small pharmacies access to the wider pharmaceutical distribution network, allowing them to search for and view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. By increasing competition and price transparency, the Trxade Exchange is giving today’s independent drugstores a new lease on life.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

In July, sales of adult-use marijuana in Canada were recorded at CA$231 million, which is a 15.2% growth. The retail sales, which equate to $175.6 million, beat the previous months’ sales record of CA$201 million ($151 million). This shows that the annual Canadian cannabis market may be worth about CA$2.8 billion ($2.1bn).

Statistics Canada reported last Friday that the monthly sales of regulated recreation marijuana had increased in all Canadian provinces. Ontario, which is the largest province with regard to population, recorded a 23.5% increase in monthly sales, which translates to CA$60.3 million ($45.3million). This increase comes after Ontario’s marijuana store license count exceeded 100 in the month of June.

CEO and co-founder of Sessions Cannabis, Steven Fry, has launched five retail outlets in Ontario thus far and is planning to open an additional 27 come April 2021. This will help address Ontario’s deficiency in marijuana retail stores. Earlier in July, two new Sessions outlets launched in Ontario. Fry stated that both stores experienced significant weekly sales increments.

He added that the growth trend would continue, as physical stores had proved to be far more popular in comparison with online sales stores in Ontario.

Fry stated that people preferred visiting the physical store locations and engaging with the staff, as they learnt more about the products and had any questions they had answered.

Alberta recorded sales of CA$51.8 million ($38.3million) in July, which translated to a 10.9% monthly growth. The province, which has many more marijuana outlets per capita as compared to any other province, beat out the more populated provinces like British Columbia and Quebec.

Quebec has relatively fewer stores in comparison to the other provinces but recreational marijuana sales in the province increase by 9.8%, which is roughly CA$11.9 million ($8.9million), on a monthly basis.

Additionally, the province of British Columbia recorded recreation marijuana sales of CA$34.6 million ($26million), which is a 17.6% increase.

In Manitoba, retail sales grew 10.8% to CA$9.1 million ($6.8million), while the Saskatchewan province recorded the smallest retail sales increase of 6.8%, an equivalent of CA$11.9 million ($8.9million).

July marijuana retails sales were as follows in eastern Canada:

• In New Brunswick sales were CA$6.4 million, which is a +20.9% growth.
• In Nova Scotia recorded sales worth CA$6.9 million; a 12.2% increase.
• In the Prince Edward Island sales were worth CA$1.5 million; a remarkable 35.3% increment.
• Lastly, in Newfoundland sales were recorded at CA$4.1 million, which equates to a 25.3% growth.

The figures above represent July sales and with the upward trend that is observed, retail sales are bound to grow as Canada’s marijuana market flourishes. These numbers are likely to serve as a massive encouragement to entities like The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) as they look forward to the time when the U.S. federal government legalizes pot sales.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

• POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition
• Founder calls contract “major milestone,” validation of move into new facility
• POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization

Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since being acquired by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The contract calls for Soluble Biotech’s expertise in protein expression and solubility studies.

“Our first contract is a major milestone and validates our recent move into a new, larger facility,” said Soluble Biotech founder Dr. Larry DeLucas, who is also a former NASA astronaut. “We quadrupled our laboratory and office space, some of which will eventually include a GMP facility. Additionally, we acquired state-of-the-art equipment to support our fermentation, therapeutic protein formulation development and protein stability studies.”

Soluble Biotech is fast becoming recognized for its ability to enhance the drug-development process by rapidly optimizing protein solubility and stability. The company brings proprietary transformational technology to formulation development for protein-based pharmaceutical and vaccines. In addition, its solubilization and stability technology is used at academic, pharmaceutical and government laboratories involved in conducting fundamental protein research.

“With our first contract on the books, and expanded capacity, the future is bright,” said DeLucas. “We are currently negotiating several additional contracts with biotechnology and pharmaceutical companies.”

In addition to this POAI milestone, the company also announced that its Skyline Medical division has sold eight of its proprietary STREAMWAY systems to a large Virginia-based university hospital organization for use in a new surgical center (https://ibn.fm/JQ6AA); the hospital system previously purchased two STREAMWAY systems, which are currently in use.

The FDA-approved and CE-marked STREAMWAY Systems provide automated, direct-to-drain medical fluid disposal that is changing the way health-care facilities collect and dispose of potentially infectious waste fluid. The eight-system sale brings the total systems sold for Q3 2020 up to 13.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

In the tiny isle of Minami-tori-shima, scientists have discovered a huge deposit of rare earth elements. The lode is not physically located on the island but in the clay sediment in the south of the seamount that the island sits on. The super deposits are bits of fish scales, teeth and bones that form the element traps.

Scientists from Japan have calculated that the clay, which covers a 2500 km² zone in the south of the island, can supply four of the earth’s rare elements’ requirements for hundreds of years.

Rare earth elements have many uses in today’s world and enable firms and individuals alike to capitalize on or generate renewable energy.  These elements are used in smartphones, TVs, compact fluorescent bulbs, LED or rechargeable batteries for cars. Additionally, many military and medical technologies use them as well. This has significantly increased the consumption of these elements in the last decade.

It should be noted though that referring to these elements as rare does not mean that they are actually rare. The rare part comes in when trying to find the elements in a deposit that is minable.

Scientific Reports recently published a paper in June, where a team of Japanese scientists dated the fish fossils in the Minami-tori-shima isle and a similar site located in the South Pacific area, southeast of the Manihiki Plateau. Their aim was to discover the origin of the fossils as well as determine whether there might be other deposits elsewhere.

Their findings showed that the fish fossils were 34.4 million years old and their deposits at the Minami-tori-shima are a result of the planetary cooling that formed the Antarctic ice sheet. These fossils are mostly bones which are made of phosphate and calcium. According to the study’s co-author, Junichiro Ohta, fossilized phosphate is good at ensnaring rare earth elements. In the last 34 million years, the fish fossils slowly absorbed europium, yttrium, dysprosium and terbium from the fluid that is trapped in the clay sediments. Although the mud is highly patchy, it contains roughly 20,000 parts per million of various rare earth elements.

The team of scientists from Japan also calculated that the south of Minami-tori-shima contained 16 million tons of rare earth elements that could supply the world for between 420 to 780 years at the current consumption rates.

Currently though, as the fossils are located below more than 3 miles of water, no commercial mining operation has found a way to access the minerals. Additionally, many have concerns about the biodiversity consequences of extracting the fossils through deep-sea mining. According to a study in Trends in Ecology and Evolution that was published on July 31, the costs of mining this seabed have been underestimated and are potentially high. How high a cost is too high? Only seasoned mining companies like Energy Fuels Inc. (NYSE: American: UUUU) (TSX: EFR) can tell!

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

NetworkNewsWire Editorial Coverage: Soda sales over the past 15 years have fallen significantly, leaving major beverage brands looking for alternative ways to expand their portfolios to capture a portion of the various new craft beverages that consumers drink each day. Many of these large companies are opting to go the M&A route, recognizing the significant impact that smaller specialty brands in the space might have on their existing offerings. Companies such as The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) (WTER Profile), one of the fastest-growing enhanced water companies in the industry, could be an attractive option. In the meantime, Keurig Dr. Pepper Inc. (NYSE: KDP) recently announced the launch of Brew the Love(R) Collaborations, an offering from Keurig, one of its premier brands, while Celsius Holdings Inc. (NASDAQ: CELH), maker of the leading global fitness drink, Celsuis(R), has unveiled Jackfruit, its latest addition to a diverse lineup of flavors. Another new beverage offering comes from Anheuser-Busch InBev (NYSE: BUD), which has unveiled its first zero alcohol brew, Budweiser Zero. And PepsiCo Inc. (NASDAQ: PEP) is being creative with its approach to new offerings — the company has teamed up with Red Lobster to create new ways to enjoy seafood alongside the taste and variety of PepsiCo products.

• Volume sales in the carbonated soft drink have declined for 15 consecutive years.
• Specialty and niche market beverage makers offer fast entry to capture new market share.
• The Alkaline Water Company has the earmarks of a prime candidate for a strategic M&A move by one of the big brands.
• WTER has delivered record growth over the past quarter with all indications pointing to continued growth moving forward.

Desire for Health, Variety, Lead to Soda’s Decline

A recent “Beverage Industry” article noted that volume sales in the carbonated soft drink category have seen sales decline for 15 consecutive years. “Today’s consumers want both variety and healthier refreshment, trends which have negatively impacted carbonated soft drinks,” said Gary Hemphill, managing director of research for New York-based Beverage Marketing Corporation.

In the same article, Jacqueline Hiner, industry analyst for Los Angeles-based IBISWorld, noted that “the most prominent driver of this trend is the higher number of health-conscious individuals in conjunction with rising per capita disposable income. Rising disposable income levels enable consumers who enjoy the taste of carbonated beverages to splurge on craft beverages that are made with natural ingredients. However, growth in this market is expected to be tempered by the continued increase in health consciousness driving consumers to drink water.”

As Hiner noted, while soda sales are down, sales of bottled water globally are soaring. Pre-pandemic, Americans spent $18.5 billion on bottled water each year, and that was projected to rise to $22 billion by the end of 2024. According to a report from industry expert Grand View Research, the global bottled water market is expected to reach $215.12 billion by 2025 — posting a compound annual growth rate of 7.4% over the next six years. These numbers could go even higher as health-conscious consumers around the world choose water over soda. Large soda makers may want a piece of that action.

A Prime Candidate

With those numbers staring them in the face, savvy soda companies are looking for strategic ways to strengthen the bottom line. One path that many of the larger companies are taking is mergers and acquisitions. Just a few examples include Coca Cola’s acquisition of Vitamin Water for $4.2 billion and Reignwood’s $105-million acquisition of Voss. Dr. Pepper has taken the M&A route too, acquiring Core for $525 million and Bai for $1.2 billion.

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) appears to be a prime target for this type of strategic consolidation. One of the fastest-growing enhanced water companies in the country, WTER has posted an astonishing 62% compound annual sales growth rate over the last five years. The company reported record annual revenue of $41.1 million as a health-conscious world has turned away from sugary soft drinks to bottled water, particularly water that’s been enhanced in some way .

The pandemic has only enhanced the company’s appeal. While other beverage companies struggled to put product on the shelf, The Alkaline Water Company delivered record growth over the past quarter. The company reported record sales in March ($6.2 million) and April ($7.1 million), representing year over year growth of 114% and 171% respectively.

Alkaline88 was one of the few water brands able to deliver during the peak “pantry-stuffing” period, resulting in an estimated 30–40% of new households trying Alkaline88 for the first time—the largest sampling program in the company’s history. In fact, a recent Nielsen report ranked Alkaline88(R) as the 10th best-selling value-added water and the third fastest-growing, top-ten, value-added water in the country during the 13 weeks ending May 16, 2020.

Top Brand in Value-Added Water Category

The Alkaline Water Company looks likely to continue its upward trajectory.

Alkaline88 remains one of the top-selling brands in the value-added water category. According to recent trade data, Alkaline88 reported double-digit growth despite the value added water category contracting 8.2% for the four-week period ending April 18, 2020.

In addition, the company’s track record of recognizing and meeting consumers’ needs looks strong. Last year, the company launched A88 Infused(TM) to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven all-natural flavors, with new flavors on their way.

Another point worth noting is the company’s strong commitment to the environment. The company kicked off 2020 with the announcement that its flagship brand, Alkaline88, was available in 500ml, single-serving aluminum bottles. “Consumers are demanding more eco-friendly choices, and we are excited to now offer a refillable, resealable, and 100% recyclable option,” said company president and CEO Richard A, Wright. “This is yet another step that the company is taking toward a more renewable future, and we remain committed to providing smarter and innovative packaging solutions for the environmentally conscious consumer.” The company has proven incredibly adept at identifying and delivering on consumer demands.

Other Catalysts for Growth

Not waiting on the majors, The Alkaline Water Company is eyeing multiple other catalysts for continued explosive growth this year, including its entrance into the hospitality space and expansion of its e-commerce presence to meet new consumer buying habits.

The company recently announced that its products will be available in more than 15,000 new retail locations, bringing total availability to an estimated 70,000 retail stores in all 50 states. In addition, the company has identified an additional 40,000 retail locations for further expansion in fiscal 2021.

With a solid sales pipeline in new and existing markets, Alkaline’s robust lineup of innovative products, and growing momentum in its lifestyle brands, The Alkaline Water Company may be a tremendous opportunity for investors interested in a high-growth company that has a strong track record of delivering on its promises. Of course, becoming a target for the majors would be an added bonus.

Opportunities for Growth, Success

The beverage industry has certainly taken a hit from wellness and health trends as well as the global pandemic, forcing large companies in the space to make significant moves to hold and expand market share.

Through Keurig(R), one of its premier brands, Keurig Dr. Pepper Inc. (NYSE: KDP) unveiled a new platform: Brew the Love® Collaborations, designed to highlight some of the brand’s biggest fans through partnerships to design their own collection. For its first-ever collaboration, Keurig partnered with renowned potter and designer Jonathan Adler on a limited-edition, beautifully designed K-Mini(R) Brewer with matching mug, which is available at Target and online. In addition, a K-Cup(R) Pod Canister will be available later this year.

Celsius Holdings Inc. (NASDAQ: CELH) has a new beverage choice on the market. Jackfruit, a new flavor available in the company’s Celsius Heat(TM) line, has a tropical flavor with a burst of sweetness and a tangy twist. A carbonated performance energy drink, Celcius Heat is packed with 2,000 mg of L-citrulline and 300 mg of caffeine, as well as the Celsius(R) proprietary blend. “Jackfruit is another great-tasting option that further expands our line of flavors, and we expect it will entice fans and new consumers alike,” said Celsius Holdings CEO John Fieldly. “It is the perfect way to launch our new 16 oz. Heat can packaging, which will appeal to a broader audience in the rapidly expanding performance energy category.”

Anheuser-Busch InBev (NYSE: BUD) is also adding an option to its product line. Earlier this year, the company unveiled its first zero-alcohol brew, Budweiser Zero. Developed and co-founded in partnership with NBA legend, entrepreneur and advocate Dwyane Wade, this zero-sugar, 50-calorie beverage offers a refreshing, full-flavored taste. The alcohol-free beer category is a rapidly evolving space with exciting growth opportunities. Budweiser has more than a century of brewing heritage and a legacy of category-setting innovation, making it a perfect brew to provide drinkers with the freedom of choice.

PepsiCo Inc. (NASDAQ: PEP) is also making the most of prestigious partnerships. PepsiCo is working with Red Lobster to leverage their well-known food and beverage brands in the creation of a variety of craveable new menu items, starting with the DEW(R) Garita, the first official MTN DEW(R) cocktail. The DEW Garita pairs perfectly with Red Lobster’s Cheddar Bay Biscuits(R). Made using a top-secret recipe, the new cocktail will be available at  select Red Lobster restaurants in September and will be available nationwide by the end of 2020.

The news isn’t all bad for those involved in the beverage world. Smart companies are making strategic decisions to move in directions that make the most of opportunities for growth and success.

For more information about The Alkaline Water Company, please visit The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER).

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

• SRAX’s BIGtoken’s platform allows companies to gain transparent, instant insights from platform’s 16.7+ million subscribers
• BIGtoken surveyed US user-base in early April and again in August in bid to track changes in US consumer behavior
• Actionable insights gleaned from survey reveal US citizens’ consumption habits

SRAX Inc. (NASDAQ: SRAX), a digital marketing pioneer focused on providing consumer data management services, has recently published the results of a series of surveys carried out by BIGtoken, its proprietary consumer insights platform. BIGtoken enables its platform’s user base of over 16.7 million consumers to both own their data and monetize it in an efficient and transparent manner; in turn, the platform’s customers can submit questionnaires and surveys to BIGtoken’s subscribers, receiving rapid and actionable consumer data in return  to help them better understand and serve their chosen audiences (http://nnw.fm/ltG0B).

In early April, amidst the early throes of the COVID-19 pandemic, BIGtoken surveyed its United States user base to understand how the pandemic had affected their social behaviors. The company subsequently redeployed the same survey in August to compare the results.

The results provided a fascinating insight into the consumption patterns of US-based individuals while also illustrating a remarkable shift in their daily routines over the past few months. The initial feedback regarding social behavior proved to be especially revealing:

• Less people are isolating alone today (29%) than they were four months ago (44%)
• The most popular activities for passing time at home during the pandemic have been streaming movies & TV shows, cooking or baking, playing video games, and using social media
• In April, 43% of respondents said they were exercising more than they were in the prior month. In August however, only 31% said they were exercising more than they were in the previous 4 months
• When asked, in April, “How has social distancing affected the frequency of communication with friends and family?” 42% of respondents said they were communicating more than usual. When asked again in August, only 32% said they were communicating more than usual
• In April, 70% were shopping online, while in August, only 25% were shopping online

Interestingly, while the survey results showed that consumers were less prone to be isolating alone relative to four months prior, consumption of streaming video content has enjoyed an exponential increase (particular in relation to activities such as exercise, which in turn has witnessed a marked decrease in adherents).

• 46% of respondents said in August 2020 that they are video streaming more than they were four months prior.
• More BIGtoken users have subscribed to Netflix, Amazon Prime, and Hulu from April to August 2020.
• Before the coronavirus outbreak, 21% of respondents claimed to have watched one movie per week. Currently, 32% of respondents watch two to three movies per week and 20% watch four to six movies per week.
• Generally, 50% of respondents are watching more TV and movies now than four months ago.

The survey results have matched up to actual trends, with the OTT industry seeking a surge of interest in recent months and the likes of Netflix and Disney+ adding 26 million and 54.5 million paid subscribers over the first half of the year, respectively (http://nnw.fm/aMez4).

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

On Wednesday of last week, the Trump administration announced their plan to distribute a coronavirus vaccine, free of charge, once it has been approved for use. The plan focuses on targeted groups then expands as the supply of the vaccine grows.

The government released a phased distribution using a contract that was awarded to McKesson earlier in August of this year. The first recipients of the vaccine could be:

• Healthcare workers who are likely to be exposed to the virus or those that treat and care for people who have COVID-19.
• Other essential workers
• Individuals who are at an increased risk for severe ailments as a result of COVID-19. This includes those with underlying medical conditions as well as people who are 65 years or older.

According to a transitional vaccine distribution strategy that was released on Wednesday, the final decisions depend on the proven effectiveness of the vaccines that will be developed in the Phase 3 trials.

This ‘strategy’ was written for local, state, territorial and tribal public health programs and elaborates how to plan and carry out a vaccination program within their respective areas.

Phase 1 would start after the FDA approves a vaccine. State officials are planning for administration and distribution to fixed populations and have provided local and state health departments with specific scenarios to plan for in this stage.

Phase 2 entails the distribution of the vaccines to a larger population as the vaccines become more available.

Phase 3 involves making COVID-19 vaccines available universally and ensuring they are incorporated into public and private vaccination programs.

Operation Warp Speed’s goal is to produce and administer safe and effective coronavirus vaccine doses by January 2021. There are also plans to use the federal distribution plan to form area-specific plans that will help identify vaccination areas and other logistics.

Centralized distribution allows the federal government to have full control, visibility and ability to use data to improve the vaccine uptake. These location-specific plans will also:

• Monitor adverse events and outcomes
• Identify when an individual needs a second vaccine dose
• Incorporate payment processes and claims
• Account for products that the government is spending money on to study, develop and supply.

The long-term safety of these vaccines will be evaluated through post-licensure clinical trials and pharmacovigilance surveillance. The main goal for now is to convince the public to be vaccinated. To achieve high coverage, the right messages to promote vaccine confidence need to be identified. Additionally, the CDC will work with local public health departments and partners to effectively achieve high vaccine uptake among the people. Analysts say biomedical companies like Predictive Oncology (NASDAQ: POAI) are likely to be encouraged by the preparations being made because such activities indicate that a viable vaccine is about to be released.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Most developed governments plan on phasing out internal combustion-engine vehicles over the next decade. However, one major factor stands in the way of widespread electric vehicle (“EV”) adoption: charging. While conventional vehicles have a widespread system of gas refilling stations, EV users have to use a spotty and often unreliable charging system. This, coupled with the fear of running out of charge in the middle of nowhere, has kept people from making the switch to electric vehicles.

To remove this barrier, Norway is looking to introduce a charging system that would completely change how electric vehicles are charged. From next year, 25 electric taxis in Oslo will be fitted with under-vehicle technology that will recharge wirelessly using charging pads embedded on a taxi rank. Part of a trial that authorities hope will be rolled out across the country as part of the efforts to ensure all Norwegians drive electric cars, the technology will be fitted to a test fleet of Jaguar I-Pace cars.

“The taxi industry is the ideal test bed for wireless charging and indeed for high-mileage electric mobility across the board. The inherently safe, energy efficient and high powered wireless charging platform will prove critical for electric fleets, as the infrastructure is more effective than refueling a conventional vehicle,” says Jaguar Land Rover chief executive Ralf Speth. Wireless charging is one of the options considered by automakers to simplify EV charging. According to experts, short-cut technologies like wireless charging may even encourage more consumers to switch to electric vehicles.

Using taxis was a strategic decision. Like bus fleets, taxis usually have dependable routes and waiting places, making them a suitable option for test driving the new charging technology. “Before you get to electric cars there are an awful lot of vehicles such as buses and taxis and vans and others that have to go electric. There’s no feasible way to put electricity into the batteries of those vehicles easily,” explains Andrew Daga, chief executive of Momentun Dynamincs, which provides the charging system for the trial in Oslo.

As the taxis and buses wait in taxi ranks and bus stations, they can be charging their batteries. This will allow the vehicles to recharge their batteries in small amounts and at different times throughout the day instead of having to charge the entire fleet every night. “It makes sense to have a reliable system and fewer chargers with a higher utilization rate, rather than concentrate it in fewer depots each using a skyscraper’s worth of electricity.”

Experts say environmentally conscious companies like Net Element Inc. (NASDAQ: NETE) would gladly team up with firms looking for ways to make EV charging hassle-free.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

• CNS Pharmaceuticals is a clinical-stage biotechnology company developing therapies to combat aggressive cancers of the brain and central nervous system
• The company will be applying for approval to launch Phase II trials in the first quarter of 2021 for its leading drug candidate, Berubicin, which targets glioblastoma multiforme (“GBM”) brain cancer
• CNS Pharmaceuticals CEO addressed the company’s achievements and its vision for Berubicin development during the recent 22nd annual Global Investment Conference sponsored by H.C. Wainwright & Co.
• C. Wainwright is a full-service investment bank focused on capital markets and equity research in market sectors that hinge on industries encompassing the healthcare and life sciences, metals and mining, clean tech and technology and telecommunications
• CNS holds a worldwide exclusive license to the Berubicin chemical compound and intends to also launch Phase I trials for its use in pediatric brain tumor patients through its sublicensee partner WPD Pharmaceuticals, as well as to develop a second drug candidate, WP1244, which is a novel agent 500 times more potent than chemotherapy drug daunorubicin in stopping cancer proliferation

CNS Pharmaceuticals (NASDAQ: CNSP) gained an opportunity to expand the reach of its novel brain tumor-targeting drug candidate when CEO John Climaco presented the company’s achievements and vision to potential financial backers at the 22nd annual Global Investment Conference sponsored by H.C. Wainwright & Co. (https://ibn.fm/Lqryu).

CNS Pharmaceuticals has been developing unique treatments for primary and metastatic cancers of the brain and central nervous system, including lead drug candidate, Berubicin, which the company is advancing for federal approval in trials to treat the aggressive brain cancer glioblastoma multiforme (“GBM”), according to a company news release (https://ibn.fm/5mppw).

Climaco’s appearance at the three-day investment conference Sept. 14-16 granted the biopharmaceutical company access to the life sciences investment bank’s trading clients and delivered opportunities for interested parties to visit one-on-one with management team members through the conference’s virtual technology platform. A replay of the Sept. 16 presentation will be available on CNS Pharmaceuticals’ website for 90 days following the event.

CNS Pharmaceuticals has achieved a number of key milestones as part of its preparations for filing an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) later this year to launch Phase II clinical trials for Berubicin.

CNS holds a worldwide exclusive license to the Berubicin chemical compound and has obtained all the data from a Phase I clinical trial completed in 2006 that saw some notable successes. Of 25 patients who could be evaluated, 44 percent experienced a statistically significant improvement in clinical benefit and one person obtained lasting results that has left the patient cancer-free as of the last assessment on Feb. 20, 2020, according to the news release.

When the company begins the anticipated Phase 2 trial in the U.S. in Q1 2021, its sublicensee partner, WPD Pharmaceuticals, also intends to launch in Poland a Phase 2 trial for adult GBM patients along with a Phase 1 trial for pediatric patients with GBM. Meanwhile, CNS continues developing a second drug candidate, WP1244, that is a novel DNA binding agent shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in stopping tumor cell expansion.

H.C. Wainwright & Co.’s annual Global Investment Conference was an ideal place to attract the financial support necessary to help move the projects forward. The Wainwright company is a full-service, client‐focused organization focused on capital markets and equity research in market sectors that hinge on the healthcare and life science industries, the metals and mining industries, the clean tech industry and technology and telecommunications. The conference’s tracks are divided into those four categories as well as a growth track that tackles scaling, leadership and other aspects of small business success (https://ibn.fm/Rp2o5).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• SGTM entered packaging agreement with Old Castle Lawn & Garden to supply large Midwest home improvement chains
• Old Castle Lawn & Garden parent company CRH employs 80,300 people at more than 3,100 locations across 30 countries
• SGTM dispatched team to assess damage from Hurricane Laura, one of the strongest in history
• SGTMS’s Q2 results nearly doubled from Q1 to $12.3 million in revenue, $3.4 million in gross profit

As nationwide demand for environmentally sustainable solutions for waste increases, Sustainable Green Team (OTC: SGTM) –a leading provider of environmentally beneficial solutions for tree and storm waste disposal—continues to expand its footprint in the U.S. through a packaging agreement between its subsidiary Mulch Manufacturing Inc. and Old Castle Lawn & Garden to supply large home improvement chains in the Midwest. The recent agreement with Old Castle Lawn & Garden is the latest in a series of strategic moves in line with SGTM’s corporate strategy, which combines operation expansion, strategic acquisitions and internal investment—moves that have enabled the company to expand and profit at a time of global economic contraction.

As a wholly-owned subsidiary of CRH, Old Castle Lawn & Garden provides architectural products that include concrete masonry and hardscapes, packaged cement mixes, packaged lawn and garden products. Its parent company CRH is a leading global diversified building materials group that employs over 80,300 people at more than 3,100 locations across 30 countries (http://nnw.fm/PuJON).

“I am honored to have been engaged by Old Castle Lawn & Garden and to secure a packaging agreement with this global company, increasing our strategic partnerships,” said SGTM CEO and Director Tony Raynor in recent statements (http://nnw.fm/JSbFI).

SGTM provides environmentally-beneficial solutions for tree and storm waste disposal created by hurricanes, ice storms and floods into useful organic products that benefit the environment. Through its subsidiaries, the company provides tree services that include debris hauling, biomass recycling, waste removal, mulch manufacturing, packaging and sales, and most recently the production of playground surface material.

Expert predictions forecasting a very active storm season for Florida are coming to fruition (http://ibn.fm/vNvdC), evidenced by the extent of the damage created by Hurricane Laura, considered to be one of the strongest hurricanes on record as measured by maximum sustained winds (http://nnw.fm/Qt4Nz). SGTM recently reported that it dispatched its National Storm Recovery Ltd. team to assess the damage and is still on site in impacted areas. Live video coverage of the company’s strategic relief efforts can be viewed online through its social media channels (http://nnw.fm/oSdGA).

STGM has been rapidly growing despite a worldwide economic slowdown that has seen millions of businesses closed. The company’s impressive Q2 results almost doubled during the quarter and include over $12.3 million in revenue and $3.4 million in gross profit http://nnw.fm/iiGDM. As “stewards of the environment” SGTM plans to continue expanding its operations and diversifying revenue streams amid a growing business landscape that is experiencing increased demand for their organic, sustainable and environmentally-friendly products.

To learn more about Sustainable Green Team Ltd., view the investor presentation at http://nnw.fm/UpXmd.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://nnw.fm/SGTM

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

According to a Department of Financial and Professional Regulation report from the state of Illinois, cannabis sales in the state this past month of August have yet again broken another monthly record.

The report which was released on Tuesday showed how marijuana sales in the state had been increasing each month, despite the ongoing coronavirus pandemic. Last month, consumers bought more than 1.3 million cannabis products whose value was calculated to be about $64 million. Out-of-state sales (to visitors) were recorded to be roughly $17 million. The previous sales record was $61 million, which was recorded in July.

The data collected seems to support the idea that the state’s cannabis market is not only pandemic-proof but also recession-proof.

Officials from the state have stated that despite the upward trend in cannabis sales, their primary focus at the moment lies in using the tax revenue generated to reinvest in neighborhoods and communities that have been the most affected by the drug war.

The state had announced in August that since marijuana retail sales began in January, it had recorded $52 million in tax revenue within the first six months of the year. 25% of this revenue will be directed to a social equity program.

A senior cannabis advisor to Gov. Jay Robert Pritzker, Toi Hutchinson, stated that the main aim of the state was not to make money but to help people, supporting the communities that had been most affected by the drug war.

Earlier in May, the state had reported that it was availing $31.5 million in marijuana tax revenue for restorative justice grants.

All things considered, making sure the market is equitable has not been a smooth ride. Dozens of individuals who had applied for social equity licenses recently sued regulators. They were denied the opportunity to take part in a licensing lottery as they reportedly had issues with their applications. Despite the state saying that they would approve 75 applicants, only 21 individuals qualified. Some critics protest that the resources one requires in order to turn in an acceptable application only bars those who actually need these special licenses from accessing them.

On the other hand, data of out-of-state sales supports the Governor’s prediction that marijuana tourism would reinforce the state’s reserves. Before its implementation, the State had pardoned about 11,000 individuals who had marijuana convictions.

In the State of Oregon, officials have also noticed a similar upward trend in the rise of sales amid the coronavirus pandemic. Data that was released earlier this year show that adult-use marijuana product sales had risen by 60%.

This record-breaking sales report only goes to show that the cannabis industry, including The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER), was always right in asserting that the economic benefits of a legalized marijuana industry would be far-reaching.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Ursula von der Leyen, the European Commission president, announced plans for the European Union (“EU”) to play a much greater role in the health sector. The EU plans to form a new agency for biomedical research, which will be modeled on the United States Biomedical Advanced Research and Development Authority (“BARDA”). The agency will help reinforce the European Center for Disease prevention and Control and the European Medicines Agency.

The EU BARDA will also support the European Union’s readiness and capacity to counter cross-border emergencies and threats, whether they were deliberate or natural. The EU BARDA is seen as a response to criticisms from the CEOs of a couple of European pharmaceutical firms, Paul Hudson of Sanofi and Pascal Soriot of AstraZeneca, who both stated the need for Europe to have a BARDA equivalent.

Having a single agency like BARDA, had made it possible for the U.S. to negotiate purchase agreements for coronavirus vaccines for the U.S. BARDA is also overseeing ‘Operation Warp Speed’, which was set up by President Donald Trump to help encourage manufacturers, with the objective of providing 300 million doses of coronavirus vaccines to the American public by January 2021.

This was President Ursula’s first state of the union address since she came into office earlier this year. In the address, she called for the European Parliament to increase the funding for the EU’s new initiative. Von der Leyen stated that the EU response to the coronavirus pandemic showed that it could play an important role in making sure that the supply of medical equipment was running smoothly as well as in cooperating with the industry to help increase production of ventilators, diagnostics and protective equipment. She added that discussing health competences should be a priority.

What does EU BARDA bring to the table?

The EU is planning on investing €8 billion ($9.4bn) into supercomputers manufactured in Europe. This will help the industry develop EU’s next-generation microprocessors and also build a European cloud computing project, based on Franco-German’s Gaia X.

The commission also wants to establish a European e-identity system, that will be universally secure. This will help protect individual’s personal data better. Additionally, Europeans will be able to carry out transactions using their unique e-identities; anything from renting a car to paying their taxes.

Collectively, this will help reduce Europe’s dependency on foreign technologies.

Apart from technology, von der Leyen also announced CO2 target emissions for 2030, shifting the objective to 55% from 40%. To ensure the goal is met, the commission will amend all EU climate and energy laws before next summer.

She added that the green transition would not be possible without SME’s as they are the backbone of the economy and urged them to come up with green technologies that would ensure the economy’s success without damaging the planet.

What do companies like Predictive Oncology (NASDAQ: POAI) see as the likely implications of this new EU agency becoming operational? Only time will tell!

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Since the COVID-19 crisis was declared a pandemic by the World Health Organization, it has claimed the lives of more than 958,000 people worldwide. The disease was caused by the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus 2).

Across the globe, researchers, public health experts and clinicians have dedicated their energy, time and expertise to the coronavirus pandemic in an effort to rid society of this disease and restore a sense of normalcy from the warped times we now live in.

In the past 7 months, scientists have discovered and learnt a lot about the virus and the disease it causes. Despite the lack of licensed coronavirus vaccines at the moment, there are currently 145 potential vaccines in preclinical development and another 35 coronavirus vaccines in clinical development. Additionally, 46 possible therapeutics are being handled in various clinical trials. This is remarkable progress, especially for a disease that had not existed prior to January.

These are taxing times, with researchers working day and night to identify and distinguish SARS-CoV-2 as well as find out the underlying cause of the clinical ailment. The reality is that it might take a long time before things go back to normal. At this point in time though, the information researchers find out will assist in further public health and clinical research into the coronavirus crisis.

Researchers are still in the early stages of understanding both COVID-19 and SARS-CoV-2. A lot of useful information has come to light though, such as the realization that the coronavirus can cause lung damage, which may result in pneumonia or in critical cases, lung failure. Now comes the complicated part, designing research studies using lung cells to test treatments. It sounds so straightforward but it is not as there are very many things to be considered, such as the type of lung epithelial cells that should be used or whether the researchers should use immortalized cells or normal cells?

In addition to this, infectious viruses are best worked on in a containment lab. In the SARS-CoV-2 case, a containment level 3 lab is used. This slows down the whole research process as working in a high containment lab means increased procedures for disinfection and cleaning and increased time because extra precautions have to be taken when handling infected matter. Furthermore, additional protective protocols and measures are put in place within the lab to always ensure safety of individuals by limiting potential exposures.

However, despite the lack of vaccines or cure for COVID-19, we should all acknowledge the great strides that have been made by researchers as well as the sacrifices that frontline workers have made. More information will come to light on the disease and we are hopeful that we shall overcome COVID-19 and also be better prepared for any future pandemics. Experts say that is the same hope that biomedical companies like DarioHealth Corp. (NASDAQ: DRIO) have.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.